title: [Clinical efficiency of reamberin - cycloferon combination in treatment of hepatic cirrhosis associated with chronic HCV infection].
abstract: The clinical efficiency of a reamberin and cycloferon combination for the treatment of hepatic cirrhosis (HC) associated with chronic HCV infection has been studied. Immunological investigation of patients carried out before the treatment revealed a significant increase in the level of proinflammatory cytokines (CK) in serum, whereas the level of anti-inflammatory CK changed rather insignificantly. Use of the reamberin - cycloferon combination provided faster clinical-biochemical remission and, in respect of the pathogenetic state, ensured normalization of the CK profile in the blood. Based on these data, it can be considered as pathogenetically proved and clinically feasible and promising to use the reamberin - cycloferon combinations for a complex treatment of patients with HC associated with chronic HCV-infection.
authors.forename: V M
authors.initials: VM
authors.lastname: Frolov
authors.forename: Ia A
authors.initials: IaA
authors.lastname: Sotskaia
authors.forename: O V
authors.initials: OV
authors.lastname: Kruglova
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects* / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000276:immunology / Q000821:virology; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D013386:Succinates / Q000008:administration & dosage / Q000627:therapeutic use*; D058408:Th1-Th2 Balance / Q000187:drug effects; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects
chemical_list: D000166:Acridines; D000998:Antiviral Agents; D016207:Cytokines; D007369:Interferon Inducers; C549374:Reamberin; D013386:Succinates; D008536:Meglumine; C026430:10-carboxymethyl-9-acridanone